Abstract
Young biotech firms have ample opportunity to raise cash, but they need to appear more robust in order to compete with existing companies that are vying for the same funds.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
